Power frequency magnetic fields increase cell proliferation in the mammary gland of female Fischer 344 rats but not various other rat strains or substrains

Oncology

Volumn 69, Issue 6, 2006, Pages 486-498

  Fedrowitz, Maren ^a   Löscher, Wolfgang ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

7,12 Dimethylbenz a anthracene; Breast cancer; Electromagnetic fields; Melatonin; Terminal end bud

Indexed keywords

BROXURIDINE; DIMETHYLBENZ[A]ANTHRACENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST EPITHELIUM; CELL LABELING; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; ELECTROMAGNETIC FIELD; FEMALE; HEREDITY; INBRED STRAIN; MAMMARY GLAND; NONHUMAN; OUTBRED STRAIN; PRIORITY JOURNAL; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CELL PROLIFERATION; FEMALE; MAGNETICS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; RATS; RATS, INBRED F344; RATS, INBRED STRAINS;

EID: 32044450764     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091030     Document Type: Article

References (77)

1. Parkin DM: International variation. Oncogene 2004;23:6329-6340.
2. Stevens RG: Electric power use and breast cancer: a hypothesis. Am J Epidemiol 1987;125:556-561.
3. Stevens RG, Davis S, Thomas DB, Anderson LE, Wilson BW: Electric power, pineal function, and the risk of breast cancer. FASEB J 1992;6:853-860.
4. Stevens RG, Davis S: The melatonin hypothesis: electric power and breast cancer. Environ Health Perspect 1996;104:135-140.
5. Kheifets LI, Matkin CC: Industrialization, electromagnetic fields, and breast cancer risk. Environ Health Perspect 1999;107:145-154.
6. Caplan LS, Schoenfeld ER, O'Leary ES, Leske MC: Breast cancer and electromagnetic fields - a review. Ann Epidemiol 2000;10:31-44.
7. Erren TC: A meta-analysis of epidemiologic studies of electric and magnetic fields and breast cancer in women and men. Bioelectromagnetics 2001(suppl 5):S105-S119.
8. Labreche F, Goldberg MS, Valois MF, Nadon L. Richardson L, Lakhani R, Latreille B: Occupational exposures to extremely low frequency magnetic fields and postmenopausal breast cancer. Am J Ind Med 2003;44:643-652.
9. Kliukiene J, Tynes T, Andersen A: Residential and occupational exposures to 50-Hz magnetic fields and breast cancer in women: a population-based study. Am J Epidemiol 2004;159:852-861.
10. Davis S, Kaune WT, Mirick DK, Chen C, Stevens RG: Residential magnetic fields, light-atnight, and nocturnal urinary 6-sulfatoxymelatonin concentration in women. Am J Epidemiol 2001;154:591-600.
11. Van Wijngaarden E, Nylander-French LA, Millikan RC. Savitz DA, Loomis D: Population-based case-control study of occupational exposure to electromagnetic fields and breast cancer. Ann Epidemiol 2001;11:297-303.
12. Davis S, Mirick DK, Stevens RG: Residential magnetic fields and the risk of breast cancer. Am J Epidemiol 2002;155:446-454.
13. London SJ, Pogoda JM, Hwang KL, Langholz B, Monroe KR, Kolonel LN, Kaune WT, Peters JM, Henderson BE: Residential magnetic field exposure and breast cancer risk: a nested case-control study from a multiethnic cohort in Los Angeles County, California. Am J Epidemiol 2003;158:969-980.
14. Schoenfeld ER, O'Leary ES, Henderson K, Grimson R, Kabat GC, Ahnn S, Kaune WT, Gammon MD, Leske MC: Electromagnetic fields and breast cancer on Long Island: a casecontrol study. Am J Epidemiol 2003;158:47-58.
15. Fedrowitz M, Westermann J, Löscher W: Magnetic field exposure increases cell proliferation but does not affect melatonin levels in the mammary gland of female Sprague-Dawley rats. Cancer Res 2002;62:1356-1363.
16. Löscher W: Breast cancer and use of electric power: experimental studies on the melatonin hypothesis; in Bartsch C, Bartsch H, Blask DE, Cardinali DP, Hrushesky WJM, Mecke D (eds): The Pineal Gland and Cancer: Neuroimmunoendocrine Mechanisms in Malignancy. Heidelberg, Springer, 2001, pp 518-533.
17. Thun-Battersby S, Mevissen M, Löscher W: Exposure of Sprague-Dawley rats to a 50-Hertz, 100-microTesla magnetic field for 27 weeks facilitates mammary tumorigenesis in the 7,12-dimethylbenz[a]anthracene model of breast cancer. Cancer Res 1999;59:3627-3633.
18. Fedrowitz M, Kamino K, Löscher W: Significant differences in the effects of magnetic field exposure on 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in two substrains of Sprague-Dawley rats. Cancer Res 2004;64:243-251.
19. Ekströrn T, Mild KH, Holmberg B: Mammary tumours in Sprague-Dawley rats after initiation with DMBA followed by exposure to 50 Hz electromagnetic fields in a promotional scheme. Cancer Lett 1998;123:107-111.
20. Anderson LE, Boorman GA, Morris JE, Sasser LB, Mann PC, Grumbein SL, Hailey JR, McNally A, Sills RC, Haseman JK: Effect of 13 week magnetic field exposures on DMBA-initiated mammary gland carcinoma in female Sprague-Dawley rats. Carcinogenesis 1999;20:1615-1620.
21. Boorman GA, Anderson LE, Morris JE, Sasser LB, Mann PC, Grumbein SL, Hailey JR, McNally A, Sills RC, Haseman JK: Effect of 26 week magnetic field exposures in a DMBA initiation-promotion mammary gland model in Sprague-Dawley rats. Carcinogenesis 1999;20:899-904.
22. Anderson LE, Morris JE, Sasser LB, Löscher W: Effects of 50 or 60 Hertz, 100 mT magnetic field exposure in the DMBA mammary cancer model in Sprague-Dawley rats: possible explanations for different results from two laboratories. Environ Health Perspect 2000;108:797-802.
23. White WJ, Lee CS: The development and maintenance of the Crl:CD(SD)IGS BR rat breeding system; in CD(SD)IGS Study Group (ed): Biological Reference Data on CD(SD)IGS Rats - 1998. Tokyo, Best Printing, 1998, pp 8-14.
24. Baum A, Mevissen M, Kamino K, Mohr U, Löscher W: A histopathological study on alterations in DMBA-induced mammary carcinogenesis in rats with 50 Hz, 100 mT magnetic field exposure. Carcinogenesis 1995;16:119-125.
25. Mevissen M, Häubler M, Löscher W: Alterations in ornithine decarboxylase activity in the rat mammary gland after different periods of 50 Hertz magnetic field exposure. Bioelectromagnetics 1999;20:338-346.
26. Korkola JE, Archer MC: Resistance to mammary tumorigenesis in Copenhagen rats is associated with the loss of preneoplastic lesions. Carcinogenesis 1999;20:221-227.
27. Russo IH, Russo J: Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect 1996;104:938-967.
28. Russo IH, Russo J: Developmental stage of the rat mammary gland as determinant of its susceptibility to 7,12-dimethylbenz[a]anthacene, J Natl Cancer Inst 1978;61:1439-1449.
29. van Zwieten MJ, Shellabarger CJ, Hollander CF, Cramer DV, Stone JP, Holtzman S, Broerse JJ: Differences in DMBA-induced mammary neoplastic responses in two lines of Sprague-Dawley rats. Eur J Cancer Clin Oncol 1984;20:1199-1204.
30. Isobe M, Ohtsubo S, Sato A, Ogawa T, Ikeda T, Morimoto H, Eguchi K, Nakayma T: General toxicological parameters in Crj:CD (SD)IGS rats and Crj:CD (SD) rats; in CD(SD)IGS Study Group (ed): Biological Reference Data on CD(SD) IGS Rats - 1998. Tokyo, Best Printing, 1998, pp 143-154.
31. Suwa T, Murakami N, Kitagaki M, Yamaguchi M, Sasa H, Tanaka C: Characteristics of Crj: CD (SD) IGS rats compared with Crj:CD (SD) rats based on a repeated dose toxicity study; in CD(SD)IGS Study Group (ed): Biological Reference Data on CD(SD) IGS Rats - 1998. Tokyo, Best Printing, 1998, pp 82-89.
32. Kelder D, Ross SB: Differential sensitivity to 8-hydroxy-2-(di-n- propylamino)tetral in-induced corticosterone secretion and hypothermia between Sprague-Dawley rats from different breeding colonies. Pharmacol Toxicol 2001;89:295-300.
33. Festing MF: Genetic variation in outbred rats and mice and its implications for toxicological screening. J Exp Anim Sci 1993;35:210-220.
34. Isaacs JT: Inheritance of a genetic factor from the Copenhagen rat and the suppression of chemically induced mammary adenocarcinogenesis. Cancer Res 1988;48:2204-2213.
35. Kacew S, Festing MF: Role of rat strain in the differential sensitivity to pharmaceutical agents and naturally occurring substances. J Toxicol Environ Health 1996;47:1-30.
36. Mevissen M, Kietzmann M, Löscher W: In vivo exposure of rats to a weak alternating magnetic field increases ornithine decarboxylase activity in the mammary gland by a similar extent as the carcinogen DMBA. Cancer Lett 1995;90:207-214.
37. Kubatka P, Ahlersova E, Ahlers I, Bojkova B, Kalicka K, Adamekova E, Markova M, Chamilova M, Ermakova M: Variability of mammary carcinogenesis induction in female Sprague-Dawley and Wistar:Han rats: the effect of season and age. Physiol Res 2002;51:633-640.
38. Peckham JC: Experimental oncology; in Baker HJ, Lindsey JR, Weisbroth SH (eds): The Lab-oratory Rat. vol 2: Research Applications. New York, Academic Press, 1980, pp 119-147.
39. Russo J, Russo IH: Experimentally induced mammary tumors in rats. Breast Cancer Res Treat 1996;39:7-20.
40. Rao GN, Boorman GA: History of the Fischer 344 rat; in Boorman GA, Eustis SL, Elwell MR, Montgomery CA, MacKenzie WF (eds): Pathology of the Fischer Rat. San Diego, Academic Press, 1990, pp 5-8.
41. Gould MN, Zhang R: Genetic regulation of mammary carcinogenesis in the rat by susceptibility and suppressor genes. Environ Health Perspect 1991;93:161-167.
42. Haag JD, Newton MA, Gould MN: Mammary carcinoma suppressor and susceptibility genes in the Wistar-Kyoto rat. Carcinogenesis 1992;13:1933-1935.
43. Festing MFW: Inbred strains; in Baker HJ, Lindsey JR, Weisbroth SH (eds): The Laboratory Rat, vol 1: Biology and Diseases. New York, Academic Press, 1979, pp 55-72.
44. Haseman JK, Hailey JR, Morris RW: Sponta-neous neoplasm incidences in Fischer 344 rats and B6C3F1 mice in two-year carcinogenicity studies: a National Toxicology Program up-date. Toxicol Pathol 1998:26:428-441.
45. Altman NH. Goodman DG: Neoplastic dis-eases; in Baker HJ, Lindsey JR, Weisbroth SH (eds): The Laboratory Rat, vol 1: Biology and Diseases. New York, Academic Press, 1979, pp 334-376.
46. Haslam SZ: Age as a modifying factor of 7,12-dimethylbenz(a)anthracene- induced mamma-ry carcinogenesis in the Lewis rat. Int J Cancer 1979;23:374-379.
47. Rajkumar L, Guzman RC, Yang J, Thordarson G, Talamantes F, Nandi S: Prevention of mammary carcinogenesis by short-term estrogen and progestin treatments. Breast Cancer Res 2004;6:R31-R37.
48. Coenen AM, Van Luijtelaar EL: Genetic animal models for absence epilepsy: a review of the WAG/Rij strain of rats. Behav Genet 2003;33:635-655.
49. Broerse JJ, Hennen LA, Klapwijk WM, Solleveld HA: Mammary carcinogenesis in different rat strains after irradiation and hormone administration. Int J Radiat Biol Relat Stud Phys Chem Med 1987;51:1091-1100.
50. Bartstra RW, Bentvelzen PA, Zoetelief J, Mulder AH, Broerse JJ, van Bekkum DW: The effects of fractionated gamma irradiation on induction of mammary carcinoma in normal and estrogen-treated rats. Radiat Res 2000;153:557-569.
51. Lan H, Kendziorski CM, Haag JD, Shepel LA, Newton MA, Gould MN: Genetic loci controlling cancer susceptibility in the Wistar-Kyoto rat. Genetics 2001;157:331-339.
52. Hsu LC, Kennan WS, Shepel LA, Jacob HJ, Szpirer C, Szpirer J, Lander ES, Gould MN: Genetic identification of Mcs-1, a rat mammary carcinoma suppressor gene. Cancer Res 1994;54:2765-2770.
53. Isaacs JT: A mammary cancer suppressor gene and its site of action in the rat. Cancer Res 1991;51:1591-1595.
54. Bersani F: Electricity and Magnetism in Biology and Medicine. New York, Kluwer Academic/Plenum, 1999.
55. Sasser LB, Morris JE, Miller DL, Rafferty CN, Ebi KL, Anderson LE: Exposure to 60 Hz magnetic fields does not alter clinical progression of LGL leukemia in Fischer rats. Carcinogenesis 1996;17:2681-2687.
56. Boorman GA, Gauger JR, Johnson TR, Tomlinson MJ, Findlay JC, Travlos GS, McCormick DL: Eight-week toxicity study of 60 Hz magnetic fields in F344 rats and B6C3F1 mice. Fundam Appl Toxicol 1997;35:55-63.
57. Mandeville R, Franco E, Sidracghali S, Parisnadon L, Rocheleau N, Mercier G, Desy M, Gaboury L: Evaluation of the potential carcinogenicity of 60 Hz linear sinusoidal continuous-wave magnetic fields in Fischer F344 rats. FASEB J 1997;11:1127-1136.
58. Yasui M, Kikuchi T, Ogawa M, Otaka Y, Tsuchitani M, Iwata H: Carcinogenicity test of 50 Hz sinusoidal magnetic fields in rats. Bioelectromagnetics 1997;18:531-540.
59. Boorman GA, McCormick DL, Findlay JC, Hailey JR, Gauger JR, Johnson TR, Kovatch RM, Sills RC, Haseman JK: Chronic toxicity oncogenicity evaluation of 60 Hz (power frequency) magnetic fields in F344/N rats. Toxicol Pathol 1999;27:267-278.
60. Morris JE, Sasser LB, Miller DL, Dagle GE, Rafferty CN, Ebi KL, Anderson LE: Clinical progression of transplanted large granular lymphocytic leukemia in Fischer 344 rats exposed to 60 Hz magnetic fields. Bioelectromagnetics 1999;20:48-56.
61. Mandeville R, Franco E, Sidrac-Ghali S, Paris-Nadon L, Rocheleau N, Mercier G, Desy M, Devaux C, Gaboury L: Evaluation of the potential promoting effect of 60 Hz magnetic fields on N-ethyl-N-nitrosourea induced neurogenic tumors in female F344 rats. Bioelectromagnetics 2000;21:84-93.
62. Anderson LE, Morris JE, Miller DL, Rafferty CN, Ebi KL, Sasser LB: Large granular lymphocytic (LGL) leukemia in rats exposed to intermittent 60 Hz magnetic fields. Bioelectromagnetics 2001;22:185-193.
63. Tremblay L, Houde M, Mercier G, Gagnon J, Mandeville R: Differential modulation of natural and adaptive immunity in Fischer rats exposed for 6 weeks to 60 Hz linear sinusoidal continuous-wave magnetic fields. Bioelectromagnetics 1996;17:373-383.
64. Landry PS, Sadasivan KK, Marino AA, Albright JA: Electromagnetic fields can affect osteogenesis by increasing the rate of differentiation. Clin Orthop 1997;338:262-270.
65. Löscher W, Liburdy RP: Animal and cellular studies on carcinogenic effects of low frequency (50/60-Hz) magnetic fields. Mutat Res 1998;410:185-220.
66. Liburdy RP, Sloma TR, Sokolic R, Yaswen P: ELF magnetic fields, breast cancer, and melatonin: 60 Hz fields block melatonin's oncostatic action on ER and breast cancer cell proliferation. J Pineal Res 1993;14:89-97.
67. Harland JD, Liburdy RP: Environmental magnetic fields inhibit the antiproliferative action of tamoxifen and melatonin in a human breast cancer cell line. Bioelectromagnetics 1997;18:555-562.
68. Blackman CF, Benane SG, House DE: The influence of 1.2 microT. 60 Hz magnetic fields on melatonin- and tamoxifen-induced inhibition of MCF-7 cell growth. Bioelectromagnetics 2001;22:122-128.
69. Ishido M, Nitta H, Kabuto M: Magnetic fields (MF) of 50 Hz at 1.2 microT as well as 100 microT cause uncoupling of inhibitory pathways of adenylyl cyclase mediated by melatonin 1a receptor in MF-sensitive MCF-7 cells. Carcinogenesis 2001;22:1043-1048.
70. Hill SM, Blask DE: Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 1988;48:6121-6126.
71. Bartsch C, Bartsch H, Blask DE, Cardinali DP, Hrushesky WJM, Mecke D: The pineal gland and cancer. Neuroendocrine mechanisms in malignancy. Berlin, Springer, 2001.
72. Olcese J, Reuss S, Semm P: Geomagnetic field detection in rodents. Life Sci 1988;42:605-613.
73. Hong FT: Magnetic field effects on biomolecules, cells, and living organisms. Biosystems 1995;36:187-229.
74. Phillips JB, Deutschlander ME: Magnetoreception in terrestrial vertebrates: implications for possible mechanisms of EMF interaction with biological systems; in Stevens RG, Wilson BW, Anderson LE (eds): The Melatonin Hypothesis. Breast Cancer and Use of Electric Power. Columbus, Battelle Press, 1997.
75. Vollrath L: Biology of the pineal gland and melatonin in humans; in Bartsch C, Bartsch H, Blask DE, et al (eds): The Pineal Gland and Cancer. Neuroendocrine Mechanisms in Malignancy. Berlin, Springer, 2001.
76. Olcese J, Reuss S, Vollrath L: Evidence for the involvement of the visual system in mediating magnetic field effects on pineal melatonin synthesis in the rat. Brain Res 1985;333:382-384.
77. Fedrowitz M, Löscher W: Effects of magnetic field exposure in the DMBA model of breast cancer in female Fischer 344 rats. Abstract Book. 2005 Joint meeting of the Bioelectromagnetics Society and the European BioElectromagnetics Society, Dublin, 2005, pp 174-175.